ArticleeLife2024
Inhibition of ULK1/2 and KRAS
Abstract read
In one paragraph
Article in eLife, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Lysosomal metabolism in pancreatic cancer and its crosstalk with host physiology.Genes & development · 2026Review
- Lineage identity governs oncogene dependence in mouse NSCLC models of KRAS inhibitor resistance.Nature genetics · 2026Article
- Molecular insights and therapeutic implications for the tumor suppressor role of LKB1 in non-small cell lung cancer.Cancer letters · 2026Review
- Autophagy modulation in cancer.Nature reviews. Drug discovery · 2026Review
- ResMap: A community resource for systematic mapping of therapy-persistent residual cancer cell dependencies across contexts.Science advances · 2026Article
- Transcriptional and epigenetic regulation of autophagy: mechanisms, disease relevance and therapeutic opportunities.Signal transduction and targeted therapy · 2026Review
- Modulation of Oncogenic KRAS Signaling by Branched Actin-driven Cell Membrane Protrusions.Research square · 2026Article
- The dual role of the crosstalk between autophagy and ferroptosis in lung cancer treatment: Advances in mechanisms and therapeutic strategies (Review).International journal of molecular medicine · 2026Review
- Modulation of Oncogenic KRAS Signaling by Branched Actin-driven Cell Membrane Protrusions.bioRxiv : the preprint server for biology · 2026Article
- ULK1 promotes metastatic progression in experimental models of epithelial ovarian cancer.Oncogene · 2026Article
- Systematic and precise interventions for KRAS-mutant cancers.Experimental hematology & oncology · 2026Review
- ULK1 knockout suppresses pancreatic cancer progression by inhibiting autophagy and enhancing antitumor immunity.Experimental & molecular medicine · 2025Article
- Targeting LKB1/STK11-mutant cancer: distinct metabolism, microenvironment, and therapeutic resistance.Trends in pharmacological sciences · 2025Review
- Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer.Cancer research · 2025Article
- REDD1 is a determinant of the sensitivity of renal cell carcinoma cells to autophagy inhibition that can be therapeutically exploited by targeting PIM activity.Cancer letters · 2025Article
- Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2- breast cancer.NPJ breast cancer · 2025Article
- Genetics and biology of pancreatic ductal adenocarcinoma.Genes & development · 2025Review
- Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma.Journal of gastrointestinal cancer · 2025Review
- Autophagy in the lung: guardian of homeostasis or driver of disease.Autophagy reports · 2025Review
- Synergistic anticancer effects of camptothecin and sotorasib inFrontiers in pharmacology · 2025Article
Corrections and comments
- Update of
Authors and funding
13 authors.
Phaedra C GhaziDepartment of Oncological Sciences, University of Utah, Salt Lake City, United States.ORCID https://orcid.org/0000-0002-0884-9442
Kayla T O'TooleDepartment of Oncological Sciences, University of Utah, Salt Lake City, United States.
Sanjana Srinivas BoggaramDepartment of Oncological Sciences, University of Utah, Salt Lake City, United States.
Michael T ScherzerDepartment of Oncological Sciences, University of Utah, Salt Lake City, United States.
Mark R SilvisDepartment of Oncological Sciences, University of Utah, Salt Lake City, United States.
Yun ZhangDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, United States.
Madhumita BogdanDeciphera Pharmaceuticals, St. Lawrence, United States.
Bryan D SmithDeciphera Pharmaceuticals, St. Lawrence, United States.
Guillermina LozanoDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, United States.ORCID https://orcid.org/0000-0001-8985-4886
Daniel L FlynnDeciphera Pharmaceuticals, St. Lawrence, United States.
Eric L SnyderDepartment of Oncological Sciences, University of Utah, Salt Lake City, United States.ORCID https://orcid.org/0000-0003-3591-3195
Conan G KinseyDepartment of Oncological Sciences, University of Utah, Salt Lake City, United States.ORCID https://orcid.org/0000-0001-5614-8627
Martin McMahonDepartment of Oncological Sciences, University of Utah, Salt Lake City, United States.ORCID https://orcid.org/0000-0003-2812-1042
Funding
UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6MCTSA UM1 Program at University of UtahUM1TR004409 · NCATS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI RACHEL HESS, Jennifer Juhl Majersik · 2023 to 2026
$21.9MRole of p53 Missense Mutations on Tumorigenesis in VivoR01CA082577 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LOZANO, GUILLERMINA · 1999 to 2024
$7.3MStudying the initiation, progression and therapy of lung cancer in mouse modelsR01CA131261 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI MARTIN MCMAHON · 2009 to 2026
$5.3MTranscriptional Regulation of Lung Cancer IdentityR01CA212415 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Eric Lee Snyder · 2017 to 2026
$3.2MPatho-Genetic Analysis of Invasive Mucinous Adenocarcinoma of the LungR01CA240317 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI MAEDA, YUTAKA, SNYDER, ERIC LEE · 2020 to 2024
$3.1MTargeting Oncogenic NRAS, BRAF plus PI3'-Kinase Signaling for Melanoma TherapyR01CA176839 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI MARTIN MCMAHON · 2013 to 2026
$2.9MLineage Specifiers Governing Pancreatic Cancer Growth and Molecular SubtypeR01CA237404 · NCI · UNIVERSITY OF UTAH · PI SNYDER, ERIC LEE · 2020 to 2024
$1.9MResistance Mechanisms to Combined Trametinib and 4-aminoquinolones in the Inhibition of Pancreatic CancerK08CA230151 · NCI · UNIVERSITY OF UTAH · PI KINSEY, CONAN · 2020 to 2024
$1.4MHuntsman Cancer Institute (HCI) Cancer Genetics, Epigenetics, Models, and Signaling (Cancer GEMS) Training ProgramT32CA265782 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Donald E Ayer, Sheri L Holmen · 2023 to 2026
$1.0MInvestigating KRAS Signaling and Autophagy Co-inhibition in KRAS-mutant Lung CancerF31CA261116 · NCI · UNIVERSITY OF UTAH · PI GHAZI, PHAEDRA · 2022 to 2024
$89kNCATS NIH HHS UM1 TR004409NCI NIH HHS F31 CA261116NCI NIH HHS F31CA261116NCI NIH HHS K08 CA230151NCI NIH HHS K08CA230151NCI NIH HHS P30 CA042014NCI NIH HHS P30CA042014NCI NIH HHS R01 CA082577NCI NIH HHS R01 CA131261NCI NIH HHS R01CA131261NCI NIH HHS R01 CA176839NCI NIH HHS R01CA176839NCI NIH HHS R01 CA212415NCI NIH HHS R01CA212415NCI NIH HHS R01 CA237404NCI NIH HHS R01CA237404NCI NIH HHS R01 CA240317NCI NIH HHS R01CA240317NCI NIH HHS R01CA82577NCI NIH HHS T32 CA265782
Abstract
Mutational activation of
Indexed as
Autophagy-Related Protein-1 HomologCell ProliferationIntracellular Signaling Peptides and ProteinsLung NeoplasmsProto-Oncogene Proteins p21(ras)AnimalsAntineoplastic AgentsAutophagyCarcinoma, Non-Small-Cell LungCell Line, TumorDisease Models, AnimalFemaleHumansMaleMicePiperazinesAntineoplastic AgentsAutophagy-Related Protein-1 HomologHras protein, mouseIntracellular Signaling Peptides and ProteinsKRAS protein, humanPiperazinesProtein Serine-Threonine KinasesProto-Oncogene Proteins p21(ras)PyridinesPyrimidinessotorasibULK1 protein, humanUlk1 protein, mouseUlk2 protein, humanUlk2 protein, mouseautophagycancer biologyKRASLKB1lung cancermouseTP53ULK
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.